Study results released today in The New England Journal of Medicine gave the world of stroke care more evidence that physicians are winning the battle against this debilitating disease, which affects as many as one in six people. 

In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific SYNERGY Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure (TLF).

ACE is proud to announce that four new Pennsylvania facilities have received accreditation for percutaneous coronary intervention (PCI) services. To receive PCI accreditation, facilities without onsite open-heart surgery must meet the highest standards of PCI care as defined both by ACE and the Commonwealth of Pennsylvania.

When it comes to hearts, men and women are not created equally. Women who have experienced a heart attack have a higher risk of a subsequent heart attack, or death, compared to men, according to the American Heart Association. To help women live long and well with heart disease, the Cigna Foundation today announced a $100,000 World of Difference grant to New York University College of Nursing (NYUCN) to pilot and test Helping Women Help Themselves to Improve Heart Health.

At five years, the Zilver PTX stent proved to be a durable treatment for peripheral artery disease with sustained benefit, results presented Nov. 4 at the 2014 Vascular Interventional Advances (VIVA) meeting showed.

Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations, Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européene) mark and international launch of the Resolute Onyx Drug-Eluting Stent (DES). The first live patient implant of the Resolute Onyx DES occurred recently during the XII International Course of Endovascular and Myocardial Therapy in Madrid, Spain. The Resolute Onyx Drug-Eluting Stent is not approved in the United States.

Victorian Hospitals will be better equipped to measure the quality of care for their cardiac patients, under a new project that collects and compares data on coronary angioplasty practice.

As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System in underserved patient populations, including women and people of color. The Promus PREMIER Stent System is the company's latest durable polymer drug-eluting stent (DES) and is approved by the U.S. Food and Drug Administration (FDA) to treat coronary artery disease. Wayne Batchelor, M.D., F.A.C.C., F.S.C.A.I., and co-principal investigator, enrolled the first patient in the PLATINUM Diversity trial at Tallahassee Memorial Hospital, in Tallahassee, Florida.